Control of anticoagulant therapy and quality of life of patients with atrial fibrillation (review)

Control of anticoagulant therapy and quality of life of patients with atrial fibrillation (review)

The review presents the published data on the relevance of the problem of thromboembolic complications in atrial fibrillation, the peculiarities of anticoagulant therapy for this disease. The relationship of clinical characteristics of patients with anticoagulant dose adjustment algorithms has been...

Full description

Bibliographic Details
Main Authors:	Shvarts Y.G., Artanova E.L.
Format:	Article
Language:	Russian
Published:	Saratov State Medical University 2012-06-01
Series:	Саратовский научно-медицинский журнал
Subjects:	atrial fibrillation clinical trials qualitative research quality of life warfarin
Online Access:	http://www.ssmj.ru/system/files/201202_258-265.pdf

Similar Items

QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL
by: E. L. Artanova, et al.
Published: (2015-12-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

Cognitive impairment in patients with atrial fibrillation: What is the importance of anticoagulant therapy?
by: Giovanni Capobianco
Published: (2018-06-01)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01)

Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy
by: D. A. Napalkov, et al.
Published: (2019-09-01)

Outpatient Management of Oral Anticoagulation Therapy in Patients with Nonvalvular Atrial Fibrillation
by: Aida Kulo, et al.
Published: (2009-11-01)

Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
by: Emre Ozdemir, et al.
Published: (2020-01-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012-05-01)

Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2019-03-01)

Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation
by: Giuseppe Patti, et al.
Published: (2018-06-01)

Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable
by: D. A. Napalkov, et al.
Published: (2018-11-01)

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
by: Mu-Mei Hu, et al.
Published: (2017-04-01)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage
by: A. S. Gerasimenko, et al.
Published: (2021-05-01)

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)–A report on periprocedural oral anticoagulants
by: Yuji Murakawa, MD, et al.
Published: (2015-02-01)

SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS
by: E. L. Artanova, et al.
Published: (2016-01-01)

Atrial fibrillation and stroke in the perspective of new oral anticoagulants
by: Demet Funda Baş, et al.
Published: (2013-02-01)

Outcomes and direct treatment costs with novel oral anticoagulants compared to clinic-monitored warfarin for stroke prevention in atrial fibrillation
by: Hulvershorn, Sarah Elizabeth
Published: (2014)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2020-05-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting
by: Gediminas Urbonas, et al.
Published: (2019-01-01)

POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION
by: B. A. Tatarsky, et al.
Published: (2014-12-01)

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF)
by: Yuji Murakawa, MD, et al.
Published: (2017-06-01)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016-01-01)

Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
by: Carolina eMalta Hansen, et al.
Published: (2012-06-01)

Hypercoagulability in patients with atrial fibrillation and associated obesity: a way to hemorrhage or thromboembolia?
by: Yu. V. Kovbasniuk, et al.
Published: (2017-10-01)

Clinical practices of the management of nonvalvular atrial fibrillation and outcome of treatment: A representative prospective survey in tertiary healthcare centers across Turkey
by: Bülent Özin, et al.
Published: (2018-03-01)

Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience
by: Shaban Mohammed, et al.
Published: (2017-01-01)

Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
by: Tommaso Sacquegna, et al.
Published: (2015-12-01)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)

Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia
by: Sarah M. Alyousif, et al.
Published: (2016-10-01)

Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation
by: Kwang-No Lee, et al.
Published: (2019-11-01)

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2016-01-01)

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

Optimising clinical effectiveness and quality along the atrial fibrillation anticoagulation pathway: an economic analysis
by: Eoin Moloney, et al.
Published: (2019-12-01)